Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 5513 indapamid - tvrdá tobolka - 2,5mg - indapamid

Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

orion corporation, espoo array - 5513 indapamid - tableta s prodlouženým uvolňováním - 1,5mg - indapamid

Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 5513 indapamid - tableta - 0,625mg - indapamid

Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 5513 indapamid - tableta - 1,25mg - indapamid

Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 5513 indapamid - tableta - 2,5mg - indapamid

Čehija - čehu - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 5513 indapamid - tableta s prodlouženým uvolňováním - 1,5mg - indapamid

Eiropas Savienība - čehu - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymfom b-buněk - antineoplastická činidla - polivy v kombinaci s bendamustin a rituximab je indikován pro léčbu dospělých pacientů s relabující/refrakterní difuzní velkobuněčný b-lymfom (dlbcl), kteří nejsou kandidáty pro transplantaci hematopoetických kmenových buněk. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Eiropas Savienība - čehu - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastická činidla - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Eiropas Savienība - čehu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastická činidla - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Eiropas Savienība - čehu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastická činidla - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.